Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-0496-2013

SynchroMed EL, models 8626-10, 8626L-10, 8626-18, 8626L-18, 8627-10, 8627L-10, 8627-18, 8627L-18. implantable infusion pump. The pump is part of an implanted infusion system that consists of a SynchroMed EL pump and a catheter. The SynchroMed EL Infusion System is indicated for use when patient therapy requires the chronic infusion of drugs or fluids. The SynchroMed EL Infusion System with a 10 mL reservoir volume is indicated for use in the smaller patient who has insufficient body mass to support the larger SynchroMed EL pump or in patients who choose a smaller, lower profile pump when presented with the choice, when patient therapy requires the chronic infusion of drugs or fluids referred to in this manual.

Publicado el 19 de diciembre de 2012 · Inicio del retiro: 9 de noviembre de 2012

Resumen

FDA registra el retiro Z-0496-2013 de dispositivos médicos de Clase I, publicado el 19 de diciembre de 2012 e iniciado el 9 de noviembre de 2012. Empresa responsable: Medtronic Neuromodulation; Estado: Finalizado; Cantidad reportada: 174,700 devices total; Lote: All SynchroMed EL and SynchroMed II pumps. La Clase I indica una probabilidad razonable de consecuencias graves para la salud o muerte.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Medtronic notified Healthcare Professionals of the impact of unapproved drugs on the performance of the SynchroMed infusion pump system. Use of unapproved drugs with SynchroMed pumps can result in an increased risk of permanent motor stall and cessation of drug infusion. UPDATE 2/1/2016: Medtronic received approval to incorporate enhancements to the SynchroMed II pump which decreases the potential for internal electrical shorting and motor corrosion, and is retrieving any unused pumps.

Qué hacer

Voluntary: Firm initiated · Letter

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Medtronic Neuromodulation
Distribuidor
Worldwide distribution: USA (nationwide) and countries including: Canada and Mexico.
Lote
All SynchroMed EL and SynchroMed II pumps
Clasificación de riesgo
Class I
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿SynchroMed EL, models 8626-10, 8626L-10, 8626-18, 8626L-18, 8627-10, 8627L-10, 8627-18, 8627L-18. implantable infusion pump. The pump is part of an implanted infusion system that consists of a SynchroMed EL pump and a catheter. The SynchroMed EL Infusion System is indicated for use when patient therapy requires the chronic infusion of drugs or fluids. The SynchroMed EL Infusion System with a 10 mL reservoir volume is indicated for use in the smaller patient who has insufficient body mass to support the larger SynchroMed EL pump or in patients who choose a smaller, lower profile pump when presented with the choice, when patient therapy requires the chronic infusion of drugs or fluids referred to in this manual. fue retirado del mercado?

Sí. FDA publicó el retiro Z-0496-2013 el 19 de diciembre de 2012. Peligro reportado: Medtronic notified Healthcare Professionals of the impact of unapproved drugs on the performance of the SynchroMed infusion pump system. Use of unapproved drugs with SynchroMed pumps can result in an increased risk of permanent motor stall and cessation of drug infusion. UPDATE 2/1/2016: Medtronic received approval to incorporate enhancements to the SynchroMed II pump which decreases the potential for internal electrical shorting and motor corrosion, and is retrieving any unused pumps.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Letter